Investor Type | Firm |
Industries | BioTech • HealthTech (& Fitness) • Pharmaceutical (& Medicine) |
Stages | Early, Pre-Seed, Seed, Series A, Series B |
Investing | United States • Germany |
Investment Range | $100,000 - $5,000,000 |
Investment Sweet Spot | $1,500,000 |
Apollo Health Ventures is an early-stage venture capital firm operating transatlantically with offices in Berlin, Luxembourg, and Boston. They focus on investing in transformative healthcare companies that target age-related diseases and the process of aging itself. With a commitment to building next-generation companies to enhance healthy lifespans, they see biotechnology as the solution for healthier lifespans and reduced healthcare spending. The firm leverages its expertise by actively co-founding companies and investing in areas such as Biotech, HealthTech, Fitness, and Pharmaceuticals. With a minimal investment of $100,000 and a maximum of $5,000,000, Apollo Health Ventures aims for an investment sweet spot of $1,500,000. The firm specializes in various stages of investment, including Early, Pre-Seed, Seed, Series A, and Series B stages. Their investment strategy combines traditional funding with venture building, offering a unique approach to value creation both in Europe and the US. In their Venture Lab, Apollo Health Ventures partners with scientific experts to turn untapped technologies into transformational companies, thus acquiring founder shares at nominal value and providing unique upsides to their investors. The firm boasts scientific and operational expertise, the ability to build top teams, access to capital with strong syndicates, and a focus on risk minimization through conducting 'killer experiments'. They aim to identify best-in-class companies based on breakthrough science and led by outstanding founders. Apollo Health Ventures offers their portfolio companies support by leading players in follow-on investment rounds, as well as assistance in talent and leadership recruitment, guidance on R&D, and clinical trial and indication selection strategies. Since 2017, the firm has maintained an extensive network and has built trust through deep knowledge, ultimately impacting human health within the next 10 years by enabling scientific breakthroughs. The firm also shares news from their portfolio companies, recent advances in biotech, health tech, and investments, thus keeping their stakeholders informed about the latest developments in the sector.